N-(2,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide | 205039-71-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,5-Dichlorophenyl)-8-hydroxy-7-quinolinecarboxamide
• 英文别名: N-(2,5-dichlorophenyl)-8-hydroxyquinoline-7-carboxamide
• CAS: 205039-71-0
• 化学式: C₁₆H₁₀Cl₂N₂O₂
• 分子量: 333.174
• InChiKey: UMYHHBWTMJKAFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA<br/>[FR] INHIBITEURS DE L'INTERACTION CREB-CBP POUR LE TRAITEMENT DE LA LEUCÉMIE
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017156489A1

  公开（公告）日：2017-09-14

  Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.

  提供了一种抑制样本中CREB-CBP蛋白质相互作用的化合物和方法。在某些情况下，该方法包括调节过表达CREB的细胞中CREB的转录。还提供了抑制癌细胞增殖的方法。所述CREB转录抑制剂化合物包括替代水杨酰胺或其前药。还提供了一种缓解与癌症相关症状（例如急性髓细胞白血病（AML）或急性淋巴细胞白血病（ALL））的方法，适用于需要该方法的受试者。包括所述化合物的药物组合物用于治疗癌症。所述化合物可以与第二药剂（例如抗癌药剂）组合配制或提供给受试者。
• [EN] 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS<br/>[FR] 8-HYDROXYQUINOLEINES 7-SUBSTITUEES UTILISEES COMME AGENTS ANTIVIRAUX
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1998011073A1

  公开（公告）日：1998-03-19

  (EN) The present invention provides for 8-hydroxy-7-substituted quinoline compounds such as formula (IA). These compounds are useful as anti-viral agents. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).(FR) L'invention concerne des composés de 8-hydroxyquinoléine substituée en 7, représentés par la formule (IA). Ces composés sont utiles comme agents antiviraux. Ils présentent en particulier une activité antivirale contre le virus herpétique cytomégalovirus (CMV). Un grand nombre de ces composés sont également actifs contre d'autres virus herpétiques tels le virus varicelle-zona, le virus Epstein-Barr, le virus herpes simplex et le virus herpétique humain de type 8 (VHH-8).

  本发明提供了8-羟基-7-取代喹啉化合物，例如式（IA）。这些化合物可用作抗病毒剂。具体而言，这些化合物对于疱疹病毒、巨细胞病毒（CMV）具有抗病毒活性。其中许多化合物也对其他疱疹病毒，例如带状疱疹病毒、EB病毒、单纯疱疹病毒和人类疱疹病毒8型（HHV-8）具有活性。
• 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP0927164A1

  公开（公告）日：1999-07-07
• INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20210205292A1

  公开（公告）日：2021-07-08

  Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.
• US6211376B1
  申请人：——

  公开号：US6211376B1

  公开（公告）日：2001-04-03